Search

Your search keyword '"Pitcher, Brandelyn N."' showing total 25 results
Start Over Author "Pitcher, Brandelyn N."
25 results on '"Pitcher, Brandelyn N."'

2. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Author

Du, Juan, Lopez-Verges, Sandra, Pitcher, Brandelyn N, Johnson, Jeffrey, Jung, Sin-Ho, Zhou, Lili, Hsu, Katharine, Czuczman, Myron S, Cheson, Bruce, Kaplan, Lawrence, Lanier, Lewis L, and Venstrom, Jeffrey M

Subjects
Killer Cells, Natural, Cell Line, Tumor, Humans, Lymphoma, Antineoplastic Agents, Antigens, CD20, Antibodies, Neoplasm, Disease-Free Survival, Lymphocyte Activation, Antibody-Dependent Cell Cytotoxicity, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Receptors, KIR, Young Adult, Antibodies, Monoclonal, Murine-Derived, Rituximab, Killer Cells, Natural, Cell Line, Tumor, Antigens, CD20, Antibodies, Neoplasm, and over, Receptors, KIR, Monoclonal, Murine-Derived, Immunology, Oncology and Carcinogenesis, Pharmacology and Pharmaceutical Sciences
Abstract

Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for predicting clinical responses in patients. Unlicensed NK cells, defined as NK cells lacking expression of an inhibitory KIR for self-HLA class I ligands, are hyporesponsive in steady state, but are potent effectors in inflammatory conditions. We hypothesized that antitumor antibodies such as rituximab can overcome NK-cell dependence on licensing, making unlicensed NK cells important for clinical responses. Here, we examined the influences of variations in KIR and HLA class I alleles on in vitro responses to rituximab. We tested the clinical significance in a cohort of patients with follicular lymphoma treated with rituximab-containing mAb combinations, and show that rituximab triggers responses from all NK-cell populations regardless of licensing. Neither IL2 nor accessory cells are required for activating unlicensed NK cells, but both can augment rituximab-mediated ADCC. Moreover, in 101 patients with follicular lymphoma treated with rituximab-containing mAb combinations, a "missing ligand" genotype (predictive of unlicensed NK cells) is associated with a higher rate of progression-free survival. Our data suggest that the clinical efficacy of rituximab may be driven, in part, by its ability to broaden the NK-cell repertoire to include previously hyporesponsive, unlicensed NK cells. A "missing ligand" KIR and HLA class I genotype may be predictive of this benefit and useful for personalizing treatment decisions in lymphomas and other tumors.

Published
2014

3. Supplemental Figure 4 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

Author

Du, Juan, primary, Lopez-Verges, Sandra, primary, Pitcher, Brandelyn N., primary, Johnson, Jeffrey, primary, Jung, Sin-Ho, primary, Zhou, Lili, primary, Hsu, Katharine, primary, Czuczman, Myron S., primary, Cheson, Bruce, primary, Kaplan, Lawrence, primary, Lanier, Lewis L., primary, and Venstrom, Jeffrey M., primary

Published
2023
Full Text
View/download PDF

5. Supplemental Figure 3 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

Author

Du, Juan, primary, Lopez-Verges, Sandra, primary, Pitcher, Brandelyn N., primary, Johnson, Jeffrey, primary, Jung, Sin-Ho, primary, Zhou, Lili, primary, Hsu, Katharine, primary, Czuczman, Myron S., primary, Cheson, Bruce, primary, Kaplan, Lawrence, primary, Lanier, Lewis L., primary, and Venstrom, Jeffrey M., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 2 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

Author

Du, Juan, primary, Lopez-Verges, Sandra, primary, Pitcher, Brandelyn N., primary, Johnson, Jeffrey, primary, Jung, Sin-Ho, primary, Zhou, Lili, primary, Hsu, Katharine, primary, Czuczman, Myron S., primary, Cheson, Bruce, primary, Kaplan, Lawrence, primary, Lanier, Lewis L., primary, and Venstrom, Jeffrey M., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 5 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

Author

Du, Juan, primary, Lopez-Verges, Sandra, primary, Pitcher, Brandelyn N., primary, Johnson, Jeffrey, primary, Jung, Sin-Ho, primary, Zhou, Lili, primary, Hsu, Katharine, primary, Czuczman, Myron S., primary, Cheson, Bruce, primary, Kaplan, Lawrence, primary, Lanier, Lewis L., primary, and Venstrom, Jeffrey M., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 1 from CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

Author

Du, Juan, primary, Lopez-Verges, Sandra, primary, Pitcher, Brandelyn N., primary, Johnson, Jeffrey, primary, Jung, Sin-Ho, primary, Zhou, Lili, primary, Hsu, Katharine, primary, Czuczman, Myron S., primary, Cheson, Bruce, primary, Kaplan, Lawrence, primary, Lanier, Lewis L., primary, and Venstrom, Jeffrey M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data Files from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Author

Tanioka, Maki, primary, Fan, Cheng, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Hu, Zhiyuan, primary, Li, Yan, primary, Hyslop, Terry M., primary, Pitcher, Brandelyn N., primary, Soloway, Matthew G., primary, Spears, Patricia A., primary, Henry, Lynn N., primary, Tolaney, Sara, primary, Dang, Chau T., primary, Krop, Ian E., primary, Harris, Lyndsay N., primary, Berry, Donald A., primary, Mardis, Elaine R., primary, Winer, Eric P., primary, Hudis, Clifford A., primary, Carey, Lisa A., primary, and Perou, Charles M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary eTables from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Author

Tanioka, Maki, primary, Fan, Cheng, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Hu, Zhiyuan, primary, Li, Yan, primary, Hyslop, Terry M., primary, Pitcher, Brandelyn N., primary, Soloway, Matthew G., primary, Spears, Patricia A., primary, Henry, Lynn N., primary, Tolaney, Sara, primary, Dang, Chau T., primary, Krop, Ian E., primary, Harris, Lyndsay N., primary, Berry, Donald A., primary, Mardis, Elaine R., primary, Winer, Eric P., primary, Hudis, Clifford A., primary, Carey, Lisa A., primary, and Perou, Charles M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Author

Tanioka, Maki, primary, Fan, Cheng, primary, Parker, Joel S., primary, Hoadley, Katherine A., primary, Hu, Zhiyuan, primary, Li, Yan, primary, Hyslop, Terry M., primary, Pitcher, Brandelyn N., primary, Soloway, Matthew G., primary, Spears, Patricia A., primary, Henry, Lynn N., primary, Tolaney, Sara, primary, Dang, Chau T., primary, Krop, Ian E., primary, Harris, Lyndsay N., primary, Berry, Donald A., primary, Mardis, Elaine R., primary, Winer, Eric P., primary, Hudis, Clifford A., primary, Carey, Lisa A., primary, and Perou, Charles M., primary

Published
2023
Full Text
View/download PDF

13. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Author

Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., and Bernard, Philip S.

Published
2013
Full Text
View/download PDF

14. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Author

Bartlett, Nancy L., primary, Wilson, Wyndham H., additional, Jung, Sin-Ho, additional, Hsi, Eric D., additional, Maurer, Matthew J., additional, Pederson, Levi D., additional, Polley, Mei-Yin C., additional, Pitcher, Brandelyn N., additional, Cheson, Bruce D., additional, Kahl, Brad S., additional, Friedberg, Jonathan W., additional, Staudt, Louis M., additional, Wagner-Johnston, Nina D., additional, Blum, Kristie A., additional, Abramson, Jeremy S., additional, Reddy, Nishitha M., additional, Winter, Jane N., additional, Chang, Julie E., additional, Gopal, Ajay K., additional, Chadburn, Amy, additional, Mathew, Susan, additional, Fisher, Richard I., additional, Richards, Kristy L., additional, Schöder, Heiko, additional, Zelenetz, Andrew D., additional, and Leonard, John P., additional

Published
2019
Full Text
View/download PDF

15. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Author

Tanioka, Maki, primary, Fan, Cheng, additional, Parker, Joel S., additional, Hoadley, Katherine A., additional, Hu, Zhiyuan, additional, Li, Yan, additional, Hyslop, Terry M., additional, Pitcher, Brandelyn N., additional, Soloway, Matthew G., additional, Spears, Patricia A., additional, Henry, Lynn N., additional, Tolaney, Sara, additional, Dang, Chau T., additional, Krop, Ian E., additional, Harris, Lyndsay N., additional, Berry, Donald A., additional, Mardis, Elaine R., additional, Winer, Eric P., additional, Hudis, Clifford A., additional, Carey, Lisa A., additional, and Perou, Charles M., additional

Published
2018
Full Text
View/download PDF

16. Long‐term trajectories of self‐reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance)

Author

Mandelblatt, Jeanne S., primary, Clapp, Jonathan D., additional, Luta, Gheorghe, additional, Faul, Leigh Anne, additional, Tallarico, Michelle D., additional, McClendon, Trina D., additional, Whitley, Jessica A., additional, Cai, Ling, additional, Ahles, Tim A., additional, Stern, Robert A., additional, Jacobsen, Paul B., additional, Small, Brent J., additional, Pitcher, Brandelyn N., additional, Dura‐Fernandis, Estrella, additional, Muss, Hyman B., additional, Hurria, Arti, additional, Cohen, Harvey J., additional, and Isaacs, Claudine, additional

Published
2016
Full Text
View/download PDF

17. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Author

Carey, Lisa A., primary, Berry, Donald A., additional, Cirrincione, Constance T., additional, Barry, William T., additional, Pitcher, Brandelyn N., additional, Harris, Lyndsay N., additional, Ollila, David W., additional, Krop, Ian E., additional, Henry, Norah Lynn, additional, Weckstein, Douglas J., additional, Anders, Carey K., additional, Singh, Baljit, additional, Hoadley, Katherine A., additional, Iglesia, Michael, additional, Cheang, Maggie Chon U., additional, Perou, Charles M., additional, Winer, Eric P., additional, and Hudis, Clifford A., additional

Published
2016
Full Text
View/download PDF

18. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Author

Liu, Minetta C, primary, Pitcher, Brandelyn N, additional, Mardis, Elaine R, additional, Davies, Sherri R, additional, Friedman, Paula N, additional, Snider, Jacqueline E, additional, Vickery, Tammi L, additional, Reed, Jerry P, additional, DeSchryver, Katherine, additional, Singh, Baljit, additional, Gradishar, William J, additional, Perez, Edith A, additional, Martino, Silvana, additional, Citron, Marc L, additional, Norton, Larry, additional, Winer, Eric P, additional, Hudis, Clifford A, additional, Carey, Lisa A, additional, Bernard, Philip S, additional, Nielsen, Torsten O, additional, Perou, Charles M, additional, Ellis, Matthew J, additional, and Barry, William T, additional

Published
2016
Full Text
View/download PDF

20. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

Author

Sikov, William M, primary, Barry, William T, additional, Hoadley, Katherine A, additional, Pitcher, Brandelyn N, additional, Singh, Baljit, additional, Tolaney, Sara M, additional, Kuzma, Charles S, additional, Pluard, Timothy J, additional, Somlo, George, additional, Port, Elisa R, additional, Golshan, Mehra, additional, Berry, Donald A, additional, Hahn, Olwen M, additional, Carey, Lisa A, additional, Perou, Charles M, additional, Hudis, Clifford A, additional, and Winer, Eric P, additional

Published
2015
Full Text
View/download PDF

21. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Author

Hoadley, Katherine A, primary, Barry, William T, additional, Pitcher, Brandelyn N, additional, Parker, Joel S, additional, Wilkerson, Matthew D, additional, Irvin, William, additional, Henry, Norah Lynn, additional, Tolaney, Sara M, additional, Dang, Chau, additional, Krop, Ian E, additional, Berry, Donald A, additional, Mardis, Elaine R, additional, Perou, Charles M, additional, Winer, Eric P, additional, Hudis, Clifford A, additional, and Carey, Lisa A, additional

Published
2015
Full Text
View/download PDF

22. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance)

Author

Klepin, Heidi D., primary, Pitcher, Brandelyn N., additional, Ballman, Karla V., additional, Kornblith, Alice B., additional, Hurria, Arti, additional, Winer, Eric P., additional, Hudis, Clifford, additional, Cohen, Harvey J., additional, Muss, Hyman B., additional, and Kimmick, Gretchen G., additional

Published
2014
Full Text
View/download PDF

24. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901

Author

Sheppard, Vanessa B., primary, Faul, Leigh Anne, additional, Luta, George, additional, Clapp, Jonathan D., additional, Yung, Rachel L., additional, Wang, Judy Huei-yu, additional, Kimmick, Gretchen, additional, Isaacs, Claudine, additional, Tallarico, Michelle, additional, Barry, William T., additional, Pitcher, Brandelyn N., additional, Hudis, Clifford, additional, Winer, Eric P., additional, Cohen, Harvey J., additional, Muss, Hyman B., additional, Hurria, Arti, additional, and Mandelblatt, Jeanne S., additional

Published
2014
Full Text
View/download PDF

25. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).

Author

Morrison, Vicki A., Jung, Sin-Ho, Johnson, Jeffrey, LaCasce, Ann, Blum, Kristie A., Bartlett, Nancy L., Pitcher, Brandelyn N., and Cheson, Bruce D.

Subjects
LYMPHOMAS, MANTLE cell lymphoma, BORTEZOMIB, ANTINEOPLASTIC agents, BORONIC acids
Abstract

Cancer and Leukemia Group B designed a phase II trial of lenalidomide + bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete/partial responders (CR, PR) received maintenance lenalidomide (days 1-14) and bortezomib (days 1/8), every 21 days. Primary endpoint was overall response rate; secondary endpoints were CR rate, progression-free (PFS), event-free (EFS) and overall survival (OS). Fifty-three eligible patients, median age 67 years, were accrued. Median number of cycles received was 4 (range, 1-82). Median followup was 46 (range, 12-67) months. Best response was CR 15%, PR 25%. 5/8 CR, and 4/13 PR patients received maintenance. Six CR and one PR patient remain in remission (median, 3.2 years). Thirty-three (62%) patients have died. One-year PFS, EFS and OS are 40%, 25% and 68%, respectively. This combination will not be pursued further. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results